Wikipedia -WSS

Wikipedia

author：explore 2025-09-30 00:47:13 - browse：9762

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： 10 reasons why health care startups fail

knowledge

entertainment

WSS

Medicare drug price negotiation legal challenge met with skepticism

Micronoma's microbiome cancer diagnostic approach under fire

Adults seen as increasingly susceptible to measles

EQRx, failed developer of low

10 reasons why health care startups fail

Breakthrough Alzheimer’s drugs are inaccessible in rural states

hotspot

Wikipedia

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Vertex non

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FTC sues over Novant Health acquisition of two N.C. hospitals

New air purifier tech could be key to improving indoor air quality

Zyn nicotine pouches become unlikely player in latest culture war

At least 13 dead in Texas as scorching temps continue

Physician groups backed by private equity giant lobby on mergers

United colonoscopy coverage change 'may cost lives,' doctors say

Humana’s losses in Medicare Advantage tank its stock

hotspot

5 important ways Henrietta Lacks changed medical science

Reconstructing family trees of blood cells may help predict disease

Merck CEO won’t testify in Senate, citing no expertise in drug prices

‘Oppenheimer’ and the risks of AI in health care

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Adults seen as increasingly susceptible to measles

focus

knowledge

entertainment

focus